ATE528005T1 - 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen - Google Patents

2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen

Info

Publication number: ATE528005T1
Authority: AT; Austria
Prior art keywords: diabetes; diseases; treatment; ketoconazole; metabolic syndrome
Prior art date: 2005-01-10

Application number

AT06701304T

Other languages

English (en)

Inventor

Per Maerin

Original Assignee

Cortendo Ab Publ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-10

Publication date

2011-10-15

2006-01-10 Application filed by Cortendo Ab Publ filed Critical Cortendo Ab Publ

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE528005T1 publication Critical patent/ATE528005T1/de

Links

208000001145 Metabolic Syndrome Diseases 0.000 title abstract 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
208000014311 Cushing syndrome Diseases 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT06701304T 2005-01-10 2006-01-10 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen ATE528005T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64305505P	2005-01-10	2005-01-10
PCT/IB2006/000026 WO2006072881A1 (en)	2005-01-10	2006-01-10	Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Publications (1)

Publication Number	Publication Date
ATE528005T1 true ATE528005T1 (de)	2011-10-15

Family

ID=36143322

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06701304T ATE528005T1 (de)	2005-01-10	2006-01-10	2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen

Country Status (20)

Country	Link
US (6)	US20090233843A1 (de)
EP (1)	EP1853266B1 (de)
JP (1)	JP5358095B2 (de)
KR (2)	KR20140030327A (de)
CN (1)	CN101141964B (de)
AT (1)	ATE528005T1 (de)
AU (1)	AU2006204334B2 (de)
CA (1)	CA2594433C (de)
CY (1)	CY1112519T1 (de)
DK (1)	DK1853266T3 (de)
ES (1)	ES2377526T3 (de)
IL (1)	IL184459A (de)
MX (1)	MX2007008331A (de)
NO (1)	NO339007B1 (de)
NZ (1)	NZ560481A (de)
PL (1)	PL1853266T3 (de)
PT (1)	PT1853266E (de)
SI (1)	SI1853266T1 (de)
WO (1)	WO2006072881A1 (de)
ZA (1)	ZA200706020B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060046996A1 (en) *	2004-08-31	2006-03-02	Kowa Co., Ltd.	Method for treating hyperlipidemia
ZA200706020B (en) *	2005-01-10	2008-12-31	Cortendo Invest Ab Publ	Methods and compositions for treating diabetes, metabolic syndrome and other conditions
WO2007081980A2 (en) *	2006-01-10	2007-07-19	Diobex, Inc.	Methods and compositions for treating prostate cancer
CA2664800A1 (en) *	2006-10-02	2008-04-10	Timothy Andrew Stewart	Ketoconazole enantiomer in humans
RU2337675C1 (ru) *	2007-04-05	2008-11-10	Илья Николаевич Медведев	Способ нормализации первой фазы свертывания крови при метаболическом синдроме
RU2337680C1 (ru) *	2007-04-05	2008-11-10	Илья Николаевич Медведев	Способ восстановления функций тромбоцитов при метаболическом синдроме
RU2337686C1 (ru) *	2007-04-05	2008-11-10	Илья Николаевич Медведев	Способ оптимизации активности тромбоцитов при метаболическом синдроме
RU2337683C1 (ru) *	2007-04-05	2008-11-10	Илья Николаевич Медведев	Способ снижения активности кровяных пластинок при метаболическом синдроме
MX350088B (es)	2009-04-29	2017-08-25	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en)	2009-04-29	2017-09-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011115955A1 (en) *	2010-03-15	2011-09-22	Duke University	Identification of a genetic risk factor for diabetes
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en)	2010-11-29	2017-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US10272133B2 (en)	2011-10-06	2019-04-30	Vanderbilt University	Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US9044433B2 (en)	2011-10-06	2015-06-02	Vanderbilt University	Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CA3067012C (en)	2012-06-29	2021-10-05	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
WO2014122530A1 (en) *	2013-02-06	2014-08-14	Cortendo Ab (Publ)	Novel functionalized 4-(phenoxymethyl(-1,3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20160022752A1 (en) *	2013-03-12	2016-01-28	HMI Medical Innovations, LLC	Plant extracts with anti-diabetic and other useful activities
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US11571455B2 (en)	2013-04-11	2023-02-07	Vanderbilt University	Methods and compositions for treating alcoholic liver disease
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
CN103432135A (zh) *	2013-09-06	2013-12-11	天津市康婷生物工程有限公司	一种内源性洋地黄样因子抑制剂
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016048984A1 (en) *	2014-09-25	2016-03-31	Cortendo Ab (Publ)	Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
US20170151202A1 (en) *	2015-09-09	2017-06-01	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CN105441391A (zh) *	2015-12-10	2016-03-30	湖南中医药大学	一种糖尿病并发抑郁症的细胞模型及建立方法和应用
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
KR102114705B1 (ko) *	2017-11-06	2020-05-25	연세대학교 산학협력단	스타틴에 의한 약물유해반응의 예방 또는 치료용 약학 조성물
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US12377111B2 (en)	2018-09-28	2025-08-05	Kyungpook National University Industry-Academic Cooperation Foundation	Composition, comprising thiamine derivative, for prevention or treatment of hypercortisolemia
EP3863634B1 (de) *	2018-10-12	2026-04-08	Strongbridge Dublin Limited	Levoketoconazol zur behandlung von kongenitaler adrenalhyperplasie
WO2020180784A1 (en)	2019-03-04	2020-09-10	Strongbridge Dublin Limited	Methods of treating disease with levoketoconazole
WO2020231909A1 (en) *	2019-05-11	2020-11-19	Steven Hoffman	Compositions and methods for treating bile acid associated diseases
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
MX2022009841A (es) *	2020-02-19	2022-12-13	New Frontier Labs Llc	Ésteres de ácido azelaico en el tratamiento o en la prevención de la dislipidemia y afecciones asociadas.
KR102289381B1 (ko) *	2020-03-17	2021-08-17	주식회사 대웅테라퓨틱스	당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
IL316641A (en) *	2022-05-20	2024-12-01	Corcept Therapeutics Inc	Methods for treating Cushing's syndrome and liver disorders, and reducing liver toxicity from medications administered to the patient
US20250360215A1 (en) *	2022-08-19	2025-11-27	Chiou-Hwa YUH	Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases
WO2024105519A1 (en) *	2022-11-14	2024-05-23	Piramal Pharma Limited	A process for the preparation of levoketoconazole

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4814333A (en) *	1987-07-28	1989-03-21	The Trustees Of Dartmouth College	Method for treatment of hypercortisolemic, depressed patients
US5432176A (en) *	1988-11-29	1995-07-11	The John Hopkins University	Method of retarding the progression of chronic renal failure
WO1994014447A1 (en) *	1992-12-22	1994-07-07	Sepracor, Inc.	Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
AU5851594A (en)	1992-12-22	1994-07-19	Georgetown University	Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections
US5869255A (en) *	1994-02-01	1999-02-09	The Regents Of The University Of California	Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US6642236B1 (en) *	1998-12-14	2003-11-04	Cortendo Ab	Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
PT779810E (pt)	1994-08-09	2003-11-28	Cortendo Ab	Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii
US5584790A (en)	1995-09-08	1996-12-17	Beckman Instruments, Inc.	Variable inclination centrifugation assembly for rapid separation of blood
AU1856997A (en)	1996-02-02	1997-08-22	Merck & Co., Inc.	Method for raising hdl cholesterol levels
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
US5994334A (en) *	1997-02-05	1999-11-30	University Of Maryland	Androgen synthesis inhibitors
SE9700642D0 (sv) *	1997-02-24	1997-02-24	Kronvall Stefan Med Ab	Medel och sätt för förebyggande och behandling av det metabola syndromet
BR9810378A (pt)	1997-07-01	2000-08-29	Novo Nordisk As	Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
US6613942B1 (en)	1997-07-01	2003-09-02	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
JP2002534512A (ja)	1999-01-15	2002-10-15	ノボノルディスクアクティーゼルスカブ	非ペプチドｇｌｐ−１アゴニスト
DE60012721T4 (de)	1999-03-29	2010-09-09	Uutech Ltd., Coleraine	Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
JP2002541146A (ja)	1999-04-02	2002-12-03	ニューロゲンコーポレイション	アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
BR0010651A (pt)	1999-05-17	2002-03-19	Novo Nordisk As	Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
GB9915625D0 (en) *	1999-07-02	1999-09-01	Cortendo Ab	Method
AU7726600A (en)	1999-09-28	2001-04-30	Bayer Corporation	Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
US20020055512A1 (en) *	2000-01-21	2002-05-09	Cortendo Ab.	Compositions for delivery of a cortisol antagonist
GB0001449D0 (en)	2000-01-21	2000-03-08	Cortendo Ab	Compositions
GB0118300D0 (en)	2001-07-26	2001-09-19	Cortendo Ab	Formulations
AU2003205926A1 (en) *	2002-02-07	2003-09-02	Pfizer Limited	Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
US20040180868A1 (en) *	2003-03-12	2004-09-16	Mullally John P.	Composition and method for treating inflammations by reducing C-reactive protein
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ZA200706020B (en) *	2005-01-10	2008-12-31	Cortendo Invest Ab Publ	Methods and compositions for treating diabetes, metabolic syndrome and other conditions
WO2007081980A2 (en) *	2006-01-10	2007-07-19	Diobex, Inc.	Methods and compositions for treating prostate cancer
CA2664800A1 (en) *	2006-10-02	2008-04-10	Timothy Andrew Stewart	Ketoconazole enantiomer in humans

2006
- 2006-01-10 ZA ZA200706020A patent/ZA200706020B/xx unknown
- 2006-01-10 KR KR1020147002595A patent/KR20140030327A/ko not_active Ceased
- 2006-01-10 ES ES06701304T patent/ES2377526T3/es not_active Expired - Lifetime
- 2006-01-10 AT AT06701304T patent/ATE528005T1/de active
- 2006-01-10 AU AU2006204334A patent/AU2006204334B2/en not_active Expired
- 2006-01-10 EP EP06701304A patent/EP1853266B1/de not_active Expired - Lifetime
- 2006-01-10 DK DK06701304.5T patent/DK1853266T3/da active
- 2006-01-10 SI SI200631232T patent/SI1853266T1/sl unknown
- 2006-01-10 NZ NZ560481A patent/NZ560481A/en not_active IP Right Cessation
- 2006-01-10 PT PT06701304T patent/PT1853266E/pt unknown
- 2006-01-10 PL PL06701304T patent/PL1853266T3/pl unknown
- 2006-01-10 CA CA2594433A patent/CA2594433C/en not_active Expired - Lifetime
- 2006-01-10 WO PCT/IB2006/000026 patent/WO2006072881A1/en not_active Ceased
- 2006-01-10 JP JP2007549979A patent/JP5358095B2/ja not_active Expired - Lifetime
- 2006-01-10 MX MX2007008331A patent/MX2007008331A/es active IP Right Grant
- 2006-01-10 US US11/813,662 patent/US20090233843A1/en not_active Abandoned
- 2006-01-10 KR KR1020077017684A patent/KR101387910B1/ko not_active Expired - Lifetime
- 2006-01-10 CN CN2006800048108A patent/CN101141964B/zh not_active Expired - Lifetime
2007
- 2007-07-05 IL IL184459A patent/IL184459A/en active IP Right Grant
- 2007-08-09 NO NO20074117A patent/NO339007B1/no not_active IP Right Cessation
2012
- 2012-01-12 CY CY20121100037T patent/CY1112519T1/el unknown
2016
- 2016-04-01 US US15/088,539 patent/US9918984B2/en active Active
2018
- 2018-02-01 US US15/886,437 patent/US10098877B2/en not_active Expired - Lifetime
- 2018-10-04 US US16/152,202 patent/US10517868B2/en not_active Expired - Lifetime
2019
- 2019-12-16 US US16/715,690 patent/US10835530B2/en not_active Expired - Lifetime
2020
- 2020-11-10 US US17/094,544 patent/US11478471B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US9918984B2 (en)	2018-03-20
US20180153883A1 (en)	2018-06-07
AU2006204334A1 (en)	2006-07-13
HK1118449A1 (en)	2009-02-13
CN101141964A (zh)	2008-03-12
KR101387910B1 (ko)	2014-04-25
US20210299122A1 (en)	2021-09-30
ZA200706020B (en)	2008-12-31
NO339007B1 (no)	2016-11-07
NO20074117L (no)	2007-10-01
PT1853266E (pt)	2012-01-20
US11478471B2 (en)	2022-10-25
KR20140030327A (ko)	2014-03-11
SI1853266T1 (sl)	2012-02-29
US20190070175A1 (en)	2019-03-07
CN101141964B (zh)	2013-06-05
EP1853266A1 (de)	2007-11-14
IL184459A (en)	2013-06-27
CY1112519T1 (el)	2015-12-09
US10835530B2 (en)	2020-11-17
WO2006072881A1 (en)	2006-07-13
KR20070100781A (ko)	2007-10-11
US10098877B2 (en)	2018-10-16
US20160243115A1 (en)	2016-08-25
US20090233843A1 (en)	2009-09-17
MX2007008331A (es)	2008-01-14
PL1853266T3 (pl)	2012-03-30
ES2377526T3 (es)	2012-03-28
CA2594433C (en)	2014-12-30
AU2006204334B2 (en)	2012-02-23
US20200261446A1 (en)	2020-08-20
CA2594433A1 (en)	2006-07-13
JP5358095B2 (ja)	2013-12-04
US10517868B2 (en)	2019-12-31
JP2008526830A (ja)	2008-07-24
NZ560481A (en)	2010-02-26
IL184459A0 (en)	2007-10-31
DK1853266T3 (da)	2012-02-06
EP1853266B1 (de)	2011-10-12

Legal Events

Date

Code

Title

Description

2012-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1853266

Country of ref document: EP

Publication	Publication Date	Title
DK1853266T3 (da)	2012-02-06	2S,4R-Ketoconazol til behandling af diabetes, metabolsk syndrom og øvrige tilstande
ES2318577T3 (es)	2009-05-01	Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'.
DE602007004324D1 (en)	2010-03-04	11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2010036613A8 (en)	2010-11-18	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EA200870471A1 (ru)	2009-06-30	Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
CY1112398T1 (el)	2015-12-09	Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
DE602007007473D1 (en)	2010-08-12	11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE602004011985D1 (de)	2008-04-03	Modulatoren des peroxisomproliferatoraktivierten rezeptors
GEP20135793B (en)	2013-03-25	Heteroaryls amide derivatives and their use as glucokinase activators
MY148128A (en)	2013-02-28	Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA200870462A1 (ru)	2009-04-28	Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
EA200870475A1 (ru)	2009-06-30	Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
TW200637874A (en)	2006-11-01	Peptides with neuropeptide-2 receptor (Y2R) agonist activity
SE0403006D0 (sv)	2004-12-09	New compounds
PL1706113T3 (pl)	2009-07-31	Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
TW200806311A (en)	2008-02-01	Neuropeptide-2 receptor-agonists
WO2008079610A3 (en)	2008-08-14	Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EA201000392A1 (ru)	2010-10-29	Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
PT1789403E (pt)	2009-05-19	Derivados de n-(fenil-oxazol-4-ilmetoximetil)-ciclo-hexilsuccinamida e compostos relacionados como ligandos dos ppar (receptores activados de proliferadores de peroxisomas) para o tratamento da hiperlipidemia e diabetes
EA202091885A1 (ru)	2021-01-15	Формы сокристаллов аналога новобиоцина и пролина
IN2012DN03023A (de)	2015-07-31
WO2008039087A8 (en)	2009-07-09	Indoline derivatives and uses thereof
UA90039C2 (en)	2010-03-25	Neuropeptide-2 receptor-agonists
UA95815C2 (en)	2011-09-12	Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators